These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

101 related articles for article (PubMed ID: 6434656)

  • 1. [Suppressive effects of IgE antibody formation of orally administered living and killed Vibrio cholerae cells in mice].
    Komagata Y
    Kansenshogaku Zasshi; 1984 Apr; 58(4):318-26. PubMed ID: 6434656
    [No Abstract]   [Full Text] [Related]  

  • 2. The suppressive effect of circulating specific antibody on the response to oral immunisation with Vibrio cholerae.
    Horsfall DJ; Brown MA; Rowley D
    Aust J Exp Biol Med Sci; 1979 Jun; 57(3):271-8. PubMed ID: 533481
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Sublingual Adjuvant Delivery by a Live Attenuated Vibrio cholerae-Based Antigen Presentation Platform.
    Liao J; Gibson JA; Pickering BS; Watnick PI
    mSphere; 2018 Jun; 3(3):. PubMed ID: 29875145
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Assessment of antibody responses and protective immunity in cholera vaccinated subjects.
    Chaicumpa W; Pacharaprakiti C; Plueksawan W; Atthasishtha N
    Southeast Asian J Trop Med Public Health; 1980 Mar; 11(1):58-66. PubMed ID: 7403955
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [IgE antibody production by Vibrio cholerae and its cellular components].
    Komagata Y; Ghoda A
    Nihon Saikingaku Zasshi; 1983; 38(2):565-72. PubMed ID: 6887516
    [No Abstract]   [Full Text] [Related]  

  • 6. Effect of chemical and heat inactivation on the antigenicity and immunogenicity of Vibrio cholerae.
    Cryz SJ; Fürer E; Germanier R
    Infect Immun; 1982 Oct; 38(1):21-6. PubMed ID: 7141690
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Editorial Commentary: Resurrecting a Live Oral Cholera Vaccine.
    Harris JB
    Clin Infect Dis; 2016 Jun; 62(11):1336-7. PubMed ID: 27001802
    [No Abstract]   [Full Text] [Related]  

  • 8. Construction of novel vaccine strains of Vibrio cholerae co-expressing the Inaba and Ogawa serotype antigens.
    Lebens M; Karlsson SL; Källgård S; Blomquist M; Ekman A; Nygren E; Holmgren J
    Vaccine; 2011 Oct; 29(43):7505-13. PubMed ID: 21807059
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Murine antibody responses following systemic or mucosal immunization with viable or inactivated Vibrio cholerae.
    Nygren E; Holmgren J; Attridge SR
    Vaccine; 2008 Dec; 26(52):6784-90. PubMed ID: 18951939
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Local immune response in mice to Vibrio cholerae.
    Bloom LD; Rowley D
    Aust J Exp Biol Med Sci; 1979 Jun; 57(3):313-23. PubMed ID: 394733
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The vaccine candidate Vibrio cholerae 638 is protective against cholera in healthy volunteers.
    García L; Jidy MD; García H; Rodríguez BL; Fernández R; Año G; Cedré B; Valmaseda T; Suzarte E; Ramírez M; Pino Y; Campos J; Menéndez J; Valera R; González D; González I; Pérez O; Serrano T; Lastre M; Miralles F; Del Campo J; Maestre JL; Pérez JL; Talavera A; Pérez A; Marrero K; Ledón T; Fando R
    Infect Immun; 2005 May; 73(5):3018-24. PubMed ID: 15845509
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Effect of Vibrio cholerae toxoid on the levels of antibodies of the IgG, IgA and IgM classes in rabbits].
    Aleksandrowicz J; Kudelski Z
    Med Dosw Mikrobiol; 1986; 38(1):15-22. PubMed ID: 3713366
    [No Abstract]   [Full Text] [Related]  

  • 13. Immunogenicity and protective role of three formulations of oral cholera vaccine.
    Kalambaheti T; Chaisri U; Srimanote P; Pongponratn E; Chaicumpa W
    Vaccine; 1998; 16(2-3):201-7. PubMed ID: 9607031
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Plasmid-induced loss of virulence in Vibrio cholerae.
    Sinha VB; Srivastava BS
    Nature; 1978 Dec; 276(5689):708-9. PubMed ID: 732874
    [No Abstract]   [Full Text] [Related]  

  • 15. Process development for a Cuban cholera vaccine based on the attenuated strain Vibrio cholerae 638.
    Talavera A; Año G; García H; Moreira T; Delgado H; Riverón L; Gil S; Miranda A; Cedré B; Valmaseda T; Pino Y; Pérez JL; Infante JF; García L; Sierra G
    Vaccine; 2006 May; 24(18):3746-9. PubMed ID: 16085342
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Cumulative protective efficacy of rZot and rAce combination in challenge experiments with wild type Vibrio cholerae in mouse model.
    Anvari S; Najar-Peerayeh S; Behmanesh M; Bakhshi B
    Hum Vaccin Immunother; 2018; 14(9):2323-2328. PubMed ID: 29852089
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Immunogenicity and protective capacity of inactivated "vibrio cholerae" whole cell vaccines.
    Cryz SJ; Fürer E; Germanier R
    Dev Biol Stand; 1983; 53():67-72. PubMed ID: 6873478
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Intestinal colonization of the infant mouse model by attenuated and virulent Vibrio cholerae strains.
    Cedré Marrero B; García Imia LG; García Sánchez HM; Fariñas Medina M; Talavera Coronel A; Infante Bourzac JF
    Arch Med Res; 1998; 29(3):231-4. PubMed ID: 9775456
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Suppression of IgE antibody production by component of Vibrio cholerae].
    Komagata Y; Ghoda A
    Kansenshogaku Zasshi; 1984 Jan; 58(1):23-8. PubMed ID: 6434645
    [No Abstract]   [Full Text] [Related]  

  • 20. Present status of cholera vaccines.
    Levine MM; Black RE; Clements ML; Kaper JB
    Biochem Soc Trans; 1984 Apr; 12(2):200-2. PubMed ID: 6724113
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 6.